Ken Griffin Cytom X Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$559 Billion
Q4 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 3,700 shares of CTMX stock, worth $2,479. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,700

Previous 3,000 23.33%

Holding current value

$2,479

Previous $3,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.86 - $1.29 $4,465 - $6,697	5,192 Added 1.64%	322,311 $331,000
Q3 2024 Nov 14, 2024	SELL	$1.12 - $1.51 $198,826 - $268,061	-177,524 Reduced 35.89%	317,119 $374,000
Q2 2024 Aug 14, 2024	BUY	$1.21 - $5.13 $554,017 - $2.35 Million	457,866 Added 1244.98%	494,643 $603,000
Q1 2024 May 15, 2024	SELL	$1.41 - $2.74 $305,273 - $593,226	-216,506 Reduced 85.48%	36,777 $80,000
Q4 2023 Feb 14, 2024	BUY	$1.07 - $1.55 $206,635 - $299,331	193,117 Added 320.97%	253,283 $392,000
Q3 2023 Nov 14, 2023	BUY	$1.26 - $1.87 $64,653 - $95,953	51,312 Added 579.53%	60,166 $77,000
Q2 2023 Aug 14, 2023	SELL	$1.41 - $1.92 $380,450 - $518,060	-269,823 Reduced 96.82%	8,854 $15,000
Q1 2023 May 15, 2023	SELL	$1.48 - $2.88 $265,276 - $516,214	-179,241 Reduced 39.14%	278,677 $420,000
Q4 2022 Feb 14, 2023	BUY	$1.19 - $1.91 $486,423 - $780,729	408,759 Added 831.5%	457,918 $732,000
Q3 2022 Nov 14, 2022	SELL	$1.23 - $1.97 $352,800 - $565,055	-286,830 Reduced 85.37%	49,159 $71,000
Q2 2022 Aug 15, 2022	BUY	$1.53 - $2.89 $492,058 - $929,444	321,607 Added 2236.18%	335,989 $615,000
Q1 2022 May 16, 2022	SELL	$2.67 - $4.68 $63,246 - $110,859	-23,688 Reduced 62.22%	14,382 $38,000
Q4 2021 Feb 14, 2022	SELL	$3.87 - $7.39 $2.83 Million - $5.41 Million	-731,696 Reduced 95.05%	38,070 $164,000
Q2 2021 Aug 16, 2021	SELL	$6.33 - $9.91 $1.01 Million - $1.59 Million	-160,144 Reduced 17.22%	769,766 $4.87 Million
Q1 2021 May 17, 2021	BUY	$6.6 - $9.0 $4.91 Million - $6.7 Million	744,644 Added 401.93%	929,910 $7.19 Million
Q4 2020 Feb 16, 2021	SELL	$6.47 - $7.9 $618,920 - $755,714	-95,660 Reduced 34.05%	185,266 $1.21 Million
Q3 2020 Nov 16, 2020	BUY	$6.55 - $8.83 $1.39 Million - $1.88 Million	212,861 Added 312.73%	280,926 $1.87 Million
Q2 2020 Aug 14, 2020	SELL	$7.4 - $14.64 $991,903 - $1.96 Million	-134,041 Reduced 66.32%	68,065 $567,000
Q1 2020 May 15, 2020	SELL	$3.61 - $8.6 $842,801 - $2.01 Million	-233,463 Reduced 53.6%	202,106 $1.55 Million
Q4 2019 Feb 14, 2020	BUY	$5.17 - $8.91 $1.05 Million - $1.81 Million	203,094 Added 87.36%	435,569 $3.62 Million
Q3 2019 Nov 14, 2019	BUY	$7.38 - $12.25 $1.72 Million - $2.85 Million	232,475 New	232,475 $1.72 Million
Q2 2019 Aug 14, 2019	SELL	$9.35 - $11.41 $320,611 - $391,248	-34,290 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$9.5 - $19.16 $68,485 - $138,124	7,209 Added 26.62%	34,290 $0
Q3 2018 Nov 13, 2018	BUY	$18.04 - $26.41 $83,020 - $121,538	4,602 Added 20.47%	27,081 $0
Q2 2018 Aug 10, 2018	SELL	$21.38 - $29.68 $524,601 - $728,258	-24,537 Reduced 52.19%	22,479 $0
Q1 2018 May 11, 2018	BUY	$21.76 - $34.22 $1.02 Million - $1.61 Million	47,016 New	47,016 $1.34 Million

Others Institutions Holding CTMX

# of Institutions

Shares Held

46.1M

Call Options Held

3.7K

Put Options Held

4.7K

View Full List

About CytomX Therapeutics, Inc.

Ticker CTMX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 65,950,200
Market Cap $44.2M
Description
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...

More about CTMX

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account